AYURCANN REPORTS RECORD SALES IN Q1 2024 FEATURING A 249% INCREASE IN GROSS REVENUE - Seite 4

Forward-looking information in this news release are based on certain assumptions and expected future events, namely: the Company has the ability to produce various derivative cannabis products; the Company will focus on custom processes and pharma grade products for the adult use and medical cannabis industry in Canada; the Company will focus on maximizing its margins and market share; the Company will continue its search for new opportunities to increase its revenues; the Company has the ability to carry out its anticipated SKUs launches under the provided timelines; the Company has the ability to reduce cost through increased efficiency in its internal processes and partnerships; the accuracy of the conclusions based on the quoted market studies; the Company has the ability to reward and retain its personnel; the Company has the ability to carry out its stated plans to sustain and grow its market share; and the Company has the ability to enhance its product development capabilities by differentiating its products with its competitors.

These statements involve known and unknown risks, uncertainties and other factors, which may cause actual results, performance or achievements to differ materially from those expressed or implied by such statements, including but not limited to: the Company’s inability to produce various derivative cannabis products; the Company’s inability to focus on custom processes and pharma grade products for the adult use and medical cannabis industry in Canada; the Company’s inability to focus on maximizing its margins and market share; the Company’s inability to continue its search for new opportunities to increase its revenues; the Company’s inability to carry out its anticipated SKUs launches under the provided timelines; the Company’s inability to reduce cost through increased efficiency in its internal processes and partnerships; the inaccuracy of the conclusions based on the quoted market studies; the Company’s inability to reward and retain its personnel; the Company’s inability to carry out its stated plans to sustain and grow its market share; and the Company’s inability to enhance its product development capabilities by differentiating its products with its competitors.